PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
29-Mar-2022 GreenBank Capital Portfolio Company CodiKoat Delivers Revolutionary Biosafety Product and Enters Into Partnerships CodiKoat
29-Mar-2022 CD Formulation Announces to Offer Nitrosamine Impurities Analysis Service for Drug Formulation Projects CD Formulation
29-Mar-2022 Telemedicine Market Size Worth Around US$ 186.7 Bn by 2027 Global Market Insights
29-Mar-2022 Accelerate Diagnostics Announces Launch Of Accelerate Arc™ Module and BC Kit Accelerate Diagnostics
29-Mar-2022 EXACT Therapeutics AS Announces Appointment of Dr Per Walday as Chief Executive Officer EXACT Therapeutics
29-Mar-2022 European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B CSL Behring
29-Mar-2022 Carthera’s SonoCloud technology demonstrates safety and therapeutic potential in clinical trial on patients living with Alzheimer’s Disease Andrew Lloyd Associates
29-Mar-2022 Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences Gadeta
29-Mar-2022 Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency Sanofi
29-Mar-2022 DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product DelSiTech
29-Mar-2022 Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020 Novo Holdings
29-Mar-2022 Oxurion to Participate in Needham Virtual Healthcare Conference Oxurion
29-Mar-2022 European marketing authorization application for MOB-015 submitted Moberg Pharma
29-Mar-2022 Publication of definitive end result for Vifor Pharma tender offer Vifor Pharma
29-Mar-2022 New Long-Term Complete Skin Clearance Data for BIMZELX®▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting Syneos Health
29-Mar-2022 Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis Sanofi
29-Mar-2022 Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies Almirall
29-Mar-2022 Oxurion Publishes 2021 Annual Report Oxurion
29-Mar-2022 Test can personalise use of immunotherapy and chemotherapy for head and neck cancer The Institute of Cancer Research
29-Mar-2022 Medtech start-up Ubiplug obtains ISO 13485:2016 certification Andrew Lloyd Associates